ALNEV — Neovacs SA Share Price
Last trade - 00:00- €0.12m
- €0.37m
- €0.53m
- 18
- 77
- 10
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.01 | ||
| Price to Tang. Book | 0.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.66% | ||
| Return on Equity | -101.77% | ||
| Operating Margin | -4347.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | 0.03 | 0.02 | 0 | 0.53 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Directors
- Hugo Brugiere CHM
- Jean-Jacques Bertrand VCH (63)
- Vincent Serra COO (52)
- Bernard Fanget VPR
- Olivier Dhellin OTH
- Baudouin Hallo DRC
- Claude Solarz DRC (75)
- Daniel Zagury DRC
- Muriel Haim IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 1st, 1992
- Public Since
- April 15th, 2010
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 9,336,740
- Address
- 14 Rue De La Republique, SURESNES, 92150
- Web
- https://www.neovacs.com/fr/
- Phone
- +33 153109300
- Auditors
- BM&A
Upcoming Events for ALNEV
Similar to ALNEV
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
As of Today at 22:14 UTC, shares in Neovacs SA are trading at €0.01. This share price information is delayed by 15 minutes.
Shares in Neovacs SA last closed at €0.01 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Neovacs SA share price has underperformed the FTSE Global All Cap Index by -100% over the past year.
The overall consensus recommendation for Neovacs SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNeovacs SA does not currently pay a dividend.
Neovacs SA does not currently pay a dividend.
Neovacs SA does not currently pay a dividend.
To buy shares in Neovacs SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.01, shares in Neovacs SA had a market capitalisation of €0.12m.
Here are the trading details for Neovacs SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALNEV
Based on an overall assessment of its quality, value and momentum Neovacs SA is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neovacs SA is €0.40. That is 2976.92% above the last closing price of €0.01.
Analysts covering Neovacs SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neovacs SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -99.57%.
As of the last closing price of €0.01, shares in Neovacs SA were trading -99.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neovacs SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Neovacs SA's management team is headed by:
- Hugo Brugiere - CHM
- Jean-Jacques Bertrand - VCH
- Vincent Serra - COO
- Bernard Fanget - VPR
- Olivier Dhellin - OTH
- Baudouin Hallo - DRC
- Claude Solarz - DRC
- Daniel Zagury - DRC
- Muriel Haim - IND